TRUE-AHF Prognostic Classification (experimental prototype)
- TRUE-AHF Prognostic Classification — explanation and clinical context
This page implements an experimental prognostic classifier inspired by common predictors used in acute heart failure (AHF) prognostic models: advanced age, low systolic blood pressure, tachycardia, elevated BUN/creatinine, hyponatremia, elevated natriuretic peptides (NT-proBNP), reduced left ventricular ejection fraction, and positive cardiac troponin. These variables have repeatedly been associated with short-term and medium-term mortality in AHF cohorts and are components of widely used tools such as the GWTG-HF and MEESSI-AHF scores. The TRUE-AHF study was a randomized trial testing ularitide in AHF and provided extensive baseline and outcome data, but there is no widely used, published “TRUE-AHF prognostic score” available to clinicians; deriving such a score would require access to the trial dataset and formal model development/validation. This prototype provides an illustrative, transparent weighting of commonly important predictors so developers can (1) replace weights with coefficients from a validated model, (2) recalibrate to local data, or (3) use the structure as a starting point when deriving a score from TRUE-AHF or another dataset.
Reference:
Packer M, et al. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF). N Engl J Med. 2017; published report of the TRUE-AHF trial.
Miró Ò, et al. Risk stratification scores for patients with acute heart failure — systematic assessments and comparisons of available tools (reviews of MEESSI, GWTG and others).
MEESSI-AHF and GWTG-HF are examples of validated AHF risk scores; consult original publications and external validations before clinical use.
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.